Healthcare >> CEO Interviews >> October 14, 2002
JOHN G. SCHULTE has been Chief Executive Officer of Consensus
Pharmaceuticals Inc. since November 2001. Most recently, Mr. Schulte was
President and CEO of Somnus Medical Technologies, a publicly held
medical device company which pioneered the use of radio frequency energy
for the minimally invasive treatment of upper airway disorders,
including sleep apnea. Somnus was recently acquired by the Gyrus Group,
PLC. Prior to Somnus, Mr. Schulte was President of Genzyme surgical
products, a $100 million division of the Genzyme Corporation which
pioneered the concept of bio-surgery, combining biomaterials, gene
therapy and cell therapy with devices to improve outcomes for
cardiovascular and general surgery. Mr. Schulte brings more than 25
years' experience in the healthcare industry, including senior
management positions with Target Therapeutics, which was acquired by
Boston Scientific, and C.R. Bard, where he was Division President of the
Interventional Cardiology Business. He also brings extensive experience
in business development from the Kendall Company, now a division of
Tyco, and the Upjohn Company. Profile
Pharmaceuticals and a picture of the company as it is now?
Mr. Schulte: Consensus Pharmaceuticals, founded in late 1998, is
